Literature DB >> 8819447

The relation between treatment benefit and underlying risk in meta-analysis.

S J Sharp1, S G Thompson, D G Altman.   

Abstract

In meta-analyses of clinical trials comparing a treated group with a control group it has been common to ask whether the treatment benefit varies according to the underlying risk of the patients in the different trials, with the hope of defining which patients would benefit most and which least from medical interventions. The usual analysis used to investigate this issue, however, which uses the observed proportions of events in the control groups of the trials as a measure of the underlying risk, is flawed and produces seriously misleading results. This arises through a bias due to regression to the mean and will be particularly acute in meta-analyses which include some small trials or in which the variability in the true underlying risks across trials is small. Approaches which previously have been thought to be more appropriate are to substitute the average proportion of events in the control and treated groups as the measure of underlying risk or to plot the proportion of events in the treated group against that in the control group (L'Abbé plot). However, these are still subject to bias in most circumstances. Because of the potentially seriously flawed conclusions that can result from such analyses, they should be replaced either by statistically appropriate (but more complex) approaches or, preferably, by analyses which investigate the dependence of the treatment effect on measured baseline characteristics of the patients in each trial.

Entities:  

Mesh:

Year:  1996        PMID: 8819447      PMCID: PMC2352108          DOI: 10.1136/bmj.313.7059.735

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  25 in total

1.  A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction.

Authors:  E M Antman; J Lau; B Kupelnick; F Mosteller; T C Chalmers
Journal:  JAMA       Date:  1992-07-08       Impact factor: 56.272

2.  Problems induced by meta-analyses.

Authors:  T C Chalmers
Journal:  Stat Med       Date:  1991-06       Impact factor: 2.373

3.  Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials.

Authors:  R Brand; H Kragt
Journal:  Stat Med       Date:  1992-12       Impact factor: 2.373

4.  Methods for assessing whether change depends on initial value.

Authors:  R J Hayes
Journal:  Stat Med       Date:  1988-09       Impact factor: 2.373

Review 5.  Meta-analysis in clinical research.

Authors:  K A L'Abbé; A S Detsky; K O'Rourke
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

6.  Desmopressin and blood loss after cardiac surgery.

Authors:  M Cattaneo; P M Mannucci
Journal:  Lancet       Date:  1993-09-25       Impact factor: 79.321

7.  Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment.

Authors:  L Pagliaro; G D'Amico; T I Sörensen; D Lebrec; A K Burroughs; A Morabito; F Tiné; F Politi; M Traina
Journal:  Ann Intern Med       Date:  1992-07-01       Impact factor: 25.391

8.  Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials.

Authors:  L J Appel; E R Miller; A J Seidler; P K Whelton
Journal:  Arch Intern Med       Date:  1993-06-28

9.  Cholesterol lowering and mortality: the importance of considering initial level of risk.

Authors:  G D Smith; F Song; T A Sheldon
Journal:  BMJ       Date:  1993-05-22

10.  An evidence based approach to individualising treatment.

Authors:  P P Glasziou; L M Irwig
Journal:  BMJ       Date:  1995-11-18
View more
  32 in total

Review 1.  Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading.

Authors:  L Smeeth; A Haines; S Ebrahim
Journal:  BMJ       Date:  1999-06-05

2.  Clinical impact of simultaneous complete revascularization vs. culprit only primary angioplasty in patients with st-elevation myocardial infarction and multivessel disease: a meta-analysis.

Authors:  Eliano Pio Navarese; Stefano De Servi; Antonino Buffon; Harry Suryapranata; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

Review 3.  Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study.

Authors:  Giuseppe G L Biondi-Zoccai; Marzia Lotrionte; Antonio Abbate; Luca Testa; Enrico Remigi; Francesco Burzotta; Marco Valgimigli; Enrico Romagnoli; Filippo Crea; Pierfrancesco Agostoni
Journal:  BMJ       Date:  2006-01-16

Review 4.  Manufacturers affect clinical results of THA with zirconia heads: a systematic review.

Authors:  Hiroyuki Yoshitomi; Satoru Shikata; Hiromu Ito; Takeo Nakayama; Takashi Nakamura
Journal:  Clin Orthop Relat Res       Date:  2009-01-31       Impact factor: 4.176

5.  Regression to the mean. A threat to exercise science?

Authors:  Roy J Shephard
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

6.  Growing pains of meta-analysis.

Authors:  I Sim; M A Hlatky
Journal:  BMJ       Date:  1996-09-21

7.  Relation between treatment benefit and underlying risk in meta-analysis. Standard of "label invariance" should not be abandoned.

Authors:  S Senn
Journal:  BMJ       Date:  1996-12-14

Review 8.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 9.  Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.

Authors:  Glen S Hazlewood; Cheryl Barnabe; George Tomlinson; Deborah Marshall; Daniel J A Devoe; Claire Bombardier
Journal:  Cochrane Database Syst Rev       Date:  2016-08-29

Review 10.  Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.

Authors:  Giuseppe De Luca; Eliano Navarese; Paolo Marino
Journal:  Eur Heart J       Date:  2009-10-28       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.